Patents by Inventor Lorena Lerner

Lorena Lerner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240173267
    Abstract: The present disclosure includes, among other things, lipids, compositions, and methods useful for delivering a polynucleotide or oligonucleotide, e.g., viral genome.
    Type: Application
    Filed: January 6, 2022
    Publication date: May 30, 2024
    Applicant: Oncorus, Inc.
    Inventors: Jessica Deterling, Sean Essex, Lorena Lerner, Qi-Ying Hu, Christophe Quéva
  • Publication number: 20240166734
    Abstract: Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.
    Type: Application
    Filed: June 16, 2023
    Publication date: May 23, 2024
    Inventors: Lorena LERNER, Sandra ABBOTT, Ailin BAI, Ting CHEN, Maria Isabel CHIU, Qing LIU, Laura POLING, Nianjun TAO, Solly WEILER, Zhigang WENG, William M. WINSTON, JR., Jeno GYURIS
  • Publication number: 20240115636
    Abstract: The present disclosure relates to recombinant RNA molecules encoding an oncolytic virus genome. The present disclosure further relates to the encapsulation of the recombinant RNA molecules and the use of the recombinant RNA molecules and/or particles for the treatment and prevention of cancer.
    Type: Application
    Filed: January 6, 2022
    Publication date: April 11, 2024
    Inventors: Lorena LERNER, Edward M. KENNEDY, Christophe QUÉVA, Jessica DETERLING, Jeffrey David BRYANT, Qi-Ying HU, Tooba A. CHEEMA, Sean ESSEX
  • Patent number: 11897948
    Abstract: The invention provides methods and compositions for treating a subject having a renal-related disorder, such as chronic kidney disease (CKD), end stage renal failure, diabetes, insulin resistance, kidney hypertrophy, kidney hypotrophy, polycystic kidney disease, proteinuria, hyperglycemia, hyperuricemia, gout, kidney stones, hypertension or hypertensive nephropathy, dyslipidemia, anemia and/or reduced erythropoietin production, iron deficiency or hyperfiltration. The methods and compositions use or contain a composition that reduces or inhibits GDF15 activity.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: February 13, 2024
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Jeno Gyuris, Lorena Lerner
  • Publication number: 20230416308
    Abstract: The disclosure relates to oncolytic virus derived replicons and capsidation of the same. The disclosure also relates to the incorporation of one or more transgenes encoding payload molecules into the replicon. The disclosure further relates to the encapsulation of the replicon and/or recombinant RNA molecules encoding oncolytic viruses into particles and the use of the replicon and/or particles for the treatment and prevention of cancer.
    Type: Application
    Filed: May 28, 2021
    Publication date: December 28, 2023
    Inventors: Lorena LERNER, Edward M. KENNEDY, Jennifer S. LEE
  • Publication number: 20230295285
    Abstract: Methods are provided for improved treatment of subjects with cancer anorexia-cachexia syndrome, comprising treatment with a combination of at least one anti-cancer agent and at least one GDF15 modulator. Methods are further provided for improved treatment of subjects with anti-cancer agents which induce cachexia, comprising further treating the subject with at least one GDF15 modulator.
    Type: Application
    Filed: September 7, 2022
    Publication date: September 21, 2023
    Inventors: Jeno Gyuris, Lorena Lerner, Jie Lin
  • Patent number: 11725047
    Abstract: Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: August 15, 2023
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Lorena Lerner, Sandra Abbott, Ailin Bai, Ting Chen, Maria Isabel Chiu, Qing Liu, Laura Poling, Nianjun Tao, Solly Weiler, Zhigang Weng, William M. Winston, Jr., Jeno Gyuris
  • Publication number: 20230241140
    Abstract: Oncolytic viral vectors that incorporate one or more of the following features: viral replication restriction by insertion of microRNA (miRNA) target sequences into the viral genome; disruption of oncogenic miRNA function; cancer microenvironment remodeling; and cancer cell targeting by incorporation of protease-activated antibodies into the viral particle. Such viral vectors can be used for the treatment and prevention of cancer.
    Type: Application
    Filed: February 7, 2023
    Publication date: August 3, 2023
    Inventors: Mitchell H. FINER, Lorena LERNER, Christophe QUÉVA, Edward KENNEDY
  • Publication number: 20230227577
    Abstract: The present disclosure provides anti-DLL3 binding constructs, such as anti-DLL3 single domain antibodies, as well as polynucleotide encoding the same. Further provided are multispecific binding constructs comprising the DLL3 binding domains described herein and polynucleotides encoding the same. Methods of production of the anti-DLL3 binding constructs and their use in the treatment of cancer are also provided herein.
    Type: Application
    Filed: May 5, 2021
    Publication date: July 20, 2023
    Inventors: Gholamreza HASSANZADEH GHASSABEH, Lorena LERNER, Sonia FEAU, Christophe QUÉVA
  • Patent number: 11612625
    Abstract: Oncolytic viral vectors that incorporate one or more of the following features: viral replication restriction by insertion of microRNA (miRNA) target sequences into the viral genome; disruption of oncogenic miRNA function; cancer microenvironment remodeling; and cancer cell targeting by incorporation of protease-activated antibodies into the viral particle. Such viral vectors can be used for the treatment and prevention of cancer.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: March 28, 2023
    Assignee: Oncorus, Inc.
    Inventors: Mitchell H. Finer, Lorena Lerner, Christophe Quéva, Edward Kennedy
  • Publication number: 20220403015
    Abstract: The invention provides methods and compositions of treating a subject having a cardiac-related disorder such as congestive or chronic heart failure (CHF), cardiac hypertrophy, cardiac hypotrophy, and other cardiac myopathies/dystrophies. The methods comprise administering an effective amount of a composition that modulates, for example, reduces or inhibits, GDF15 activity in the subject.
    Type: Application
    Filed: February 2, 2022
    Publication date: December 22, 2022
    Inventors: Jeno Gyuris, Lorena Lerner
  • Publication number: 20220380735
    Abstract: The present disclosure provides dual viruses capable of producing a primary virus and a secondary virus, and dual oncolytic viruses capable of producing a primary oncolytic virus and a secondary oncolytic virus.
    Type: Application
    Filed: October 9, 2020
    Publication date: December 1, 2022
    Inventors: Edward M. KENNEDY, Lorena LERNER, Christophe QUEVA, Craig A. STRATHDEE, Jennifer S. LEE
  • Publication number: 20220117902
    Abstract: The present disclosure relates to recombinant RNA molecules encoding an oncolytic virus. The present disclosure further relates to the encapsulation of the recombinant RNA molecules and the use of the recombinant RNA molecules and/or particles for the treatment and prevention of cancer.
    Type: Application
    Filed: January 3, 2020
    Publication date: April 21, 2022
    Inventors: Lorena LERNER, Edward M. KENNEDY, Mitchell H. FINER, Christophe QUÉVA
  • Publication number: 20210403950
    Abstract: The present disclosure relates to polynucleotides comprising a nucleic acid sequence encoding a replication competent viral genome, wherein the polynucleotide is capable of producing a replication competent virus when introduced into a cell by a non-viral delivery vehicle. The present disclosure further relates to the encapsulation of the polynucleotides and the use of the polynucleotides and/or particles for the treatment and prevention of cancer.
    Type: Application
    Filed: November 13, 2019
    Publication date: December 30, 2021
    Inventors: Mitchell H. FINER, Edward KENNEDY, Lorena LERNER
  • Publication number: 20210380669
    Abstract: Selective inhibitors of repulsive guidance molecule C (RGMc), are described. Related methods, including methods for making, as well as therapeutic use of these inhibitors in the treatment of disorders, such as anemia, are also provided.
    Type: Application
    Filed: October 23, 2019
    Publication date: December 9, 2021
    Inventors: Samantha Nicholls, Adriana Donovan, Meghan McDonald, Abhishek Datta, Allan Capili, Kevin B. Dagbay, Lorena Lerner, Leonard Ira Zon, Kevin Schutz, John Bukowski, Justin W. Jackson
  • Publication number: 20210101968
    Abstract: Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.
    Type: Application
    Filed: March 19, 2020
    Publication date: April 8, 2021
    Inventors: Lorena Lerner, Sandra Abbott, Ailin Bai, Ting Chen, Maria Isabel Chiu, Qing Liu, Laura Poling, Nianjun Tao, Solly Weiler, Zhigang Weng, William M. Winston, JR., Jeno Gyuris
  • Publication number: 20200224220
    Abstract: The present disclosure relates to polynucleotides comprising a nucleic acid sequence encoding a replication competent viral genome, wherein the polynucleotide is capable of producing a replication competent virus when introduced into a cell by a non-viral delivery vehicle. The present disclosure further relates to the encapsulation of the polynucleotides and the use of the polynucleotides and/or particles for the treatment and prevention of cancer.
    Type: Application
    Filed: July 13, 2018
    Publication date: July 16, 2020
    Inventors: Mitchell H. FINER, Edward M. KENNEDY, Lorena LERNER
  • Publication number: 20200206285
    Abstract: The present disclosure relates to recombinant viral vectors for the treatment and prevention of cancer. Oncolytic viral vectors incorporate one or more of the following features: viral replication restriction by insertion of microRNA (miRNA) target sequences into the viral genome; disruption of oncogenic miRNA function; cancer microenvironment remodeling; and cancer cell targeting by incorporation of protease-activated antibodies into the viral particle.
    Type: Application
    Filed: July 26, 2018
    Publication date: July 2, 2020
    Inventors: Mitchell H. FINER, Lorena LERNER, Christophe QUÉVA, Edward KENNEDY
  • Patent number: 10597444
    Abstract: Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: March 24, 2020
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Lorena Lerner, Sandra Abbott, Ailin Bai, Ting Chen, Maria I. Chiu, Qing Liu, Laura Poling, Nianjun Tao, Solly Weiler, Zhigang Weng, William M. Winston, Jr., Jeno Gyuris
  • Publication number: 20190292251
    Abstract: The invention provides methods and compositions of treating a subject having a cardiac-related disorder such as congestive or chronic heart failure (CHF), cardiac hypertrophy, cardiac hypotrophy, and other cardiac myopathies/dystrophies. The methods comprise administering an effective amount of a composition that modulates, for example, reduces or inhibits, GDF15 activity in the subject.
    Type: Application
    Filed: November 1, 2018
    Publication date: September 26, 2019
    Inventors: Jeno Gyuris, Lorena Lerner